Nice Insight will introduce the Brand Index Plus, a more in-depth look into the annually data enabling subscribers to view their industry position according to different regions, customer segments, therapeutic categories and more.

Nice Insight will be adding 2 new CROs and 1 new CMO to the Q2 report.
+ Kemwell Biopharma
+ SNBL USA
+ WIL Research

Originally launched in Q3, Nice Insight updated and improved its dashboard feature in Q1 to provide a greater depth of information that help clients make better strategic and tactical business decisions.

Nice Insight expanded their survey respondent pool to include European-based sponsors. This enables the research team to segment the data by region, so CROs and CMOs can understand their awareness and perception in different locations. In addition, market size estimates for each service now reflect both the North American and European markets, rather than solely the North American region.

Nice Insight will be adding 2 new CROs and 10 new CMOs to the Q1 report.

+ KCAS + Avid BioServices + Corden Pharma Colorado   (Formerly Roche Colorado) + CPL + Gallus BioPharma + JHP Pharma

+ BioTrial + Next Pharma + Penn Pharma + Porton Fine Chemical + Sandoz + Sanofi

In Q1, Nice Insight is introducing a Drug Development Life Cycle tool that maps each company’s specific drug development activity against the complete drug developmental process (from Discovery to Post- Launch). In addition, subscribers will also be able to access industry benchmarks on average pricing for each activity according to phase and molecule type.

In Q4, Nice Insight is offering a Trade Show Tracker for the CROs / CMOs in our company index. The feature includes a comprehensive list of shows that companies are attending in 2012, as well as booth numbers.

In Q4, Nice Insight is offering a downloadable PDF option for the Marcom Tracker. This allows clients to access a PDF version of the visual concepts and messaging strategies of the 300+ CROs / CMOs in our company index.

Nice Insight has added a new tool, bringing added value to customers interested in publicly-traded companies. It tracks trends in stock pricing and correlates them with brand index changes for CA/CP across quarterly survey reports.

In Q3, Nice Insight is launching a Lead Generation Tool, which helps CROs and CMOs connect with qualified leads in the pharmaceutical and biotechnology industry.

In Q3, Nice Insight is launching a shopping cart feature that allows clients to choose from four different reports/pricing options. This gives clients the freedom to customize reports by purchasing intelligence on select companies at their discretion.

Nice Insight will be adding 5 new CROs to the Q3 report.
+ Accelovance
+ Dokumeds
+ Esoterix Clinical Trial Services
+ SIRO Clinpharm
+ Spaulding Clinical

In Q2, Nice Insight will add a new CRO / CMO Directory that will include regional business contact information – including names, telephone numbers and email addresses – for all companies covered in the Q1 Company Index. This directory will be also available for purchase as a standalone product.

In Q2, Nice Insight will add a new ROI Calculator to define return on marketing spending. This feature allows for more efficient marketing planning.

In Q2, Nice Insight will cover Lyophilization, Drug Delivery and PEGs in its Sector Analysis tool.

Nice Insight will add a list of new CROs / CMOs to our Company Index for Q2. Stay tuned for the latest updates.

+ Quintiles + Kendle + Helsinn + PharmaZell + Parexel + Qualicaps + Flamma s.p.a.

+ PharmaNet + ReSearch Pharmaceutical Services + Rohner Chem + Elan Drug Technologies + Dainippon Sumitomo Pharma + PRA International

Access Brand Index results, including Customer Awareness (CA) and Customer Perception (CP) scores for a select portfolio of the 300+ companies in our database.

Our new online forum feature will allow Pharmaceutical and Biotechnology suppliers and contractors to come together in one place to discuss industry issues, trends and partnership opportunities.